Sculptra
Sculptra vs. Hyaluronic Acid Fillers for the Temples
Published · Haute MD Editorial Team
For temple hollowing, the biggest difference between Sculptra and hyaluronic acid (HA) filler is FDA status, followed by how quickly each works and whether it can be reversed. HA fillers: two are FDA-approved specifically for temple hollowing in adults over 21. Juvéderm Voluma XC was approved in October 2023 and Restylane Contour in March 2026. HA adds volume at the time of injection. Sculptra (poly-L-lactic acid): its FDA-approved cosmetic uses are nasolabial folds, other facial wrinkles and fine lines in the cheek, so cosmetic use in the temples is off-label. It is given as a series of injections, and its effect builds gradually over weeks. Reversibility: HA can be broken down with an enzyme (hyaluronidase). The FDA notes that fillers not made of materials such as HA can be difficult or impossible to remove. Risks: both carry the rare but serious risk of injection into a blood vessel. Sculptra's labeling specifically lists visual disturbances, including blindness, reported after injection into the temple area. For what Sculptra temple treatment involves, see our Sculptra for temple hollowing guide. This page is general information, not medical advice.
At a glance
FDA status for temple hollowing. HA filler indicated for temples (Juvéderm Voluma XC; Restylane Contour): Approved: Voluma XC (P110033/S070, Oct 6, 2023); Restylane Contour (P140029/S054, Mar 20, 2026); both adults over 21. Sculptra (poly-L-lactic acid): Not a cosmetic indication (off-label in immune-competent adults). Labeled cosmetic uses: nasolabial folds and other facial wrinkles; cheek fine lines and wrinkles. A temple technique appears only in its HIV-lipoatrophy instructions. What it is. HA filler indicated for temples (Juvéderm Voluma XC; Restylane Contour): Hyaluronic acid gel; HA is a sugar (polysaccharide) found in skin that binds water (FDA). Sculptra (poly-L-lactic acid): Microparticles of poly-L-lactic acid, a biodegradable man-made polymer, reconstituted into a suspension before use (FDA; labeling). How the change appears. HA filler indicated for temples (Juvéderm Voluma XC; Restylane Contour): Voluma XC labeling: "temporarily adds volume to immediately lift and augment" the temple. Sculptra (poly-L-lactic acid): "Gradual correction… over several weeks" (labeling); effects "become increasingly apparent over time" (FDA). Sessions. HA filler indicated for temples (Juvéderm Voluma XC; Restylane Contour): In the FDA temple studies: an initial treatment, with an optional touch-up (Restylane Contour: offered at 1 month). Sculptra (poly-L-lactic acid): A series of injections over several months (FDA). How long it's been studied or reported to last. HA filler indicated for temples (Juvéderm Voluma XC; Restylane Contour): Voluma XC temple study: improvement "lasted for more than 1 year" in 73% of evaluated subjects at 13 months. Restylane Contour temple study: followed to 18 months. FDA's general HA guidance: approximately 6–12 months. Sculptra (poly-L-lactic acid): FDA: effects "may last up to 2 years." Cheek study (S039): results may last up to 24 months. No FDA-reviewed cosmetic temple study in its labeling. Can it be reversed?. HA filler indicated for temples (Juvéderm Voluma XC; Restylane Contour): HA can be broken down by hyaluronidase, "an enzyme that breaks down HA" (Voluma XC patient labeling). Sculptra (poly-L-lactic acid): No dissolving enzyme. FDA: removal can be difficult or impossible for fillers not made of materials such as HA. Labeled risks to ask about. HA filler indicated for temples (Juvéderm Voluma XC; Restylane Contour): Tenderness, firmness, swelling, lumps, bruising, redness; rare vascular events including vision abnormalities, blindness and stroke. Sculptra (poly-L-lactic acid): Delayed papules and nodules; must not be injected into vessels; visual disturbances including blindness reported after temple, periorbital and cheek injection.
Why FDA status matters in the temple
FDA approval is given for a specific product, for a specific use, in a specific population. For dermal fillers, the FDA says the devices are approved for adults over 21 for particular uses. It also says that "the risks associated with unapproved uses of dermal fillers… are not known.". Off-label use is legal and common in medicine, and an experienced physician may still recommend Sculptra for the temples. But since October 2023, patients have had FDA-approved HA options for this exact concern, backed by randomized, evaluator-blinded, no-treatment-controlled studies: Juvéderm Voluma XC: 205 subjects at 15 sites. At Month 3, 80.4% of treated subjects improved by at least one point on a temple-hollowing scale, vs. 13.5% of controls. Restylane Contour: randomized 4:1. At Month 3, 91.2% of treated subjects improved, vs. 9.1% of controls, and patients were followed to 18 months. These are study results, not a prediction of anyone's individual outcome. Sculptra's labeling describes pivotal studies for nasolabial folds, cheek wrinkles and HIV-associated lipoatrophy. Temples were among the areas affected in that lipoatrophy study population, but its labeling has no cosmetic temple study. Ask any physician you consult: Is the product you're recommending FDA-approved for the temples, and if not, why do you prefer it for me?
How each one works in the temple
HA fillers are gels that sit where they're placed and hold water. In the FDA temple approvals, both HA products are injected deep, on the bone (supraperiosteal). Restylane Contour's study also allowed a more superficial (subdermal) layer, using a needle or a blunt cannula. Sculptra is a suspension of poly-L-lactic acid microparticles. Its labeling warns injectors not to overcorrect "because the depression is expected to gradually improve during several weeks after injection." That gradual build is the main reason some patients and physicians prefer it, and also why you won't see the final result on the day of treatment. For what the months after treatment look like, see our Sculptra results timeline.
Reversibility and safety
The temple sits near important blood vessels. FDA labeling for both product types warns about rare but serious complications from injection into a blood vessel, including vision problems, blindness and stroke. Sculptra's labeling specifically reports visual disturbances, including blindness, after injection "into the temple area, periorbital areas, and/or cheek.". HA: labeled treatments for side effects include hyaluronidase, an enzyme that breaks down HA. Sculptra: the main labeled post-treatment reaction is delayed papules and nodules under the skin. They can appear "days to months after injection" and take a long time to resolve. There is no enzyme that dissolves it. The FDA's general advice applies to both: choose a licensed health care provider experienced in dermatology or plastic surgery and in the product being used. never buy fillers online. See Sculptra side effects and complications for more.
Which is the better fit?
This is a decision for an in-person consultation, based on your anatomy, skin and goals. These questions frame it: Do you want to see the change right away, or gradually? HA works immediately. Sculptra builds over weeks across a series of treatments. How much does reversibility matter to you? HA can be dissolved. Sculptra can't. Do you prefer an on-label product for the temples? Voluma XC and Restylane Contour are FDA-approved for temple hollowing. Sculptra is off-label there. How many visits can you commit to? Sculptra is given as a series. In the FDA temple studies, HA was an initial treatment with an optional touch-up. Who is injecting, and how often do they treat temples? Both FDA temple approvals came with conditions requiring device-specific training programs for injectors. Dosing, including the number of syringes or vials, depends on the person and is set by the treating physician. Ask for the plan and the reasoning in writing. Our Botox and filler consultation questions can help you prepare.
Find a doctor
Find a Doctor Dermatology on Haute MD Dr. Anna Avaliani: board-certified cosmetic laser surgeon on Manhattan's Upper East Side. Her profile lists Sculptra and dermal fillers for volume restoration. Dr. S. Manjula Jegasothy: board-certified dermatologist and founder of Miami Skin Institute in Coral Gables. Her profile describes a focus on non-surgical aesthetic dermatology, including dermal fillers. Her Haute MD listing includes Sculptra. Haute MD membership is a paid editorial program; inclusion is not a ranking or an endorsement of any treatment.
Sources
U.S. FDA, PMA P110033/S070, Juvéderm Voluma XC (temple indication; approved 10/06/2023), with Approval Order, Summary of Safety and Effectiveness Data, and patient labeling. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P110033S070 · https://www.accessdata.fda.gov/cdrh_docs/pdf11/P110033S070B.pdf · https://www.accessdata.fda.gov/cdrh_docs/pdf11/P110033S070D.pdf (fetched 2026-10-18). U.S. FDA, PMA P140029/S054, Restylane Contour (temple indication; approved 03/20/2026), with Approval Order and Summary of Safety and Effectiveness Data. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P140029S054 · https://www.accessdata.fda.gov/cdrh_docs/pdf14/P140029S054B.pdf (fetched 2026-10-18). U.S. FDA, PMA P140029/S057, Restylane Contour post-approval study protocol (approved 05/15/2026). https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P140029S057 (fetched 2026-10-18). U.S. FDA, PMA P030050 and P030050/S039, Sculptra (original approval and cheek indication, 04/25/2023). https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P030050 · https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P030050S039 (fetched 2026-10-18). Sculptra Instructions for Use (labeling, P030050/S039). https://www.accessdata.fda.gov/cdrh_docs/pdf3/P030050S039C.pdf (fetched 2026-10-18). U.S. FDA, "Sculptra – P030050/S039" (recently approved devices). https://www.fda.gov/medical-devices/recently-approved-devices/sculptra-p030050s039 (fetched 2026-10-18). U.S. FDA, "Dermal Fillers (Soft Tissue Fillers)." https://www.fda.gov/medical-devices/aesthetic-cosmetic-devices/dermal-fillers-soft-tissue-fillers (fetched 2026-10-18). U.S. FDA, "Dermal Fillers Approved by the Center for Devices and Radiological Health." https://www.fda.gov/medical-devices/aesthetic-cosmetic-devices/dermal-fillers-approved-center-devices-and-radiological-health (fetched 2026-10-18). Haute MD member profiles and roster (Dr. Anna Avaliani; Dr. S. Manjula Jegasothy), hauteliving.com/hautemd and /hautemd/llms-full.txt (fetched 2026-10-18). This page is for general educational purposes only and is not medical advice. It does not replace an in-person consultation with a licensed physician. Product approvals and labeling can change; your physician can explain the current status and the risks and benefits for you.
Frequently Asked Questions
Is Sculptra FDA-approved for the temples?
Not for cosmetic use. Sculptra's FDA-approved cosmetic uses are nasolabial fold contour deficiencies and other facial wrinkles, and fine lines and wrinkles in the cheek, in immune-competent people. Its labeling describes a temple technique only within its separate indication for HIV-associated facial fat loss. Cosmetic temple use is off-label.
Which fillers are FDA-approved for temple hollowing?
As of October 2026, two HA fillers: Juvéderm Voluma XC (approved October 6, 2023) and Restylane Contour (approved March 20, 2026). Both are approved for adults over 21.
Which works faster in the temples, Sculptra or HA filler?
HA filler. Voluma XC's labeling says it "temporarily adds volume to immediately lift and augment" the temple. Sculptra's labeling describes a gradual correction that builds over several weeks, across a series of injections.
Can temple filler be reversed?
HA filler can be broken down with hyaluronidase. Sculptra cannot be dissolved, and the FDA notes that fillers not made of materials such as HA can be difficult or impossible to remove.
Is temple injection risky?
All facial filler injections carry a rare risk of injection into a blood vessel, which can cause serious complications including vision loss and stroke. Sculptra's labeling specifically lists blindness reported after injection into the temple area. Choose an experienced, licensed physician and ask how they reduce and manage this risk.
How many vials or syringes will I need for my temples?
It depends on your anatomy and the degree of hollowing, and the treating physician sets the plan. Haute MD does not publish dosing or price estimates. Ask for your individual plan in writing at consultation.
Featured Haute MD Physicians
Dr. Anna Avaliani · Dr. S. Manjula Jegasothy
Browse Haute MD physiciansGet Help Now
Speak with a Haute MD Dermatology physician
Are you a Dermatology physician?
Join Haute MD Network and have your profile featured alongside these answers.
Apply for the NetworkRelated Guides
Guide · SCULPTRA
Sculptra for Temple Hollowing: What to Expect
Temple hollowing can change brow and upper-face shape. What Sculptra temple treatment involves, safety questions, and what to ask a physician.
Read GuideGuide · SCULPTRA
Sculptra Results Timeline: What to Expect at 1, 3, and 6 Months
Sculptra results develop gradually over 3-6 months. Learn what to expect after each session, when results appear, and how to track your progress.
Read GuideGuide · SCULPTRA
Sculptra Side Effects and Complications: What to Know
Sculptra's most common side effect is nodule formation. Learn how to prevent it, what other side effects to expect, and what warrants a call to your provider.
Read Guide